ZOMETA® Prostate Cancer Case Study - Medical Profile

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

ZOMETA Patient Case Study: Prostate Cancer

ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

ZOMETAŽ Prostate Cancer Patient Case Study Dieter

Dieter V.

Aged 61 years
Manages a department store
Coaches his grandson's football team

Page

1 2 3

Diagnosis and treatment of bone metastases

By February 2006, Dieter’s prostate-specific antigen (PSA) level had risen to 6.0 ng/mL
- — Chest and abdominal CT and bone scans showed no abnormalities
- — Dieter began treatment with monthly intramuscular leuprolide
Dieter’s treatment kept PSA levels undetectable until 2 months ago, when he had a PSA level of 7.1 ng/mL
Bone scan revealed an L4 lesion, confirmed as osteoblastic by lumbar spine MRI
Dieter’s urologist referred him to an oncologist for further treatment

Page

1 2 3

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US flag at the top right corner of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.